Abstract
Unbiased proteomic analyses of cell fractions, interactomes and protein modifications coupled with more targeted approaches are adding to an impressive database of the signalling pathways in platelets. In addition to the well characterised receptors that are known to exist on the platelet surface, platelet proteomic studies continue to expose novel transmembrane proteins including CD148, CLEC-2, Eph kinases and Ephrins, Frizzled-4 and -6, G6b, HIP-55, HSP47, LRP5/6 and PEAR-1. In turn identification of novel platelet receptors has led to the discovery of new platelet signalling pathways such as the collagen/CLEC-2 receptor pathway, as well as the canonical WNT pathway. This review focuses on the canonical WNT pathway, providing background information to WNT ligands, receptors and signalling pathways and then focusing on canonical WNT signalling in anucleate platelets, where the suppression of platelet activity and adhesion by its ligand, Wnt-3a has recently been demonstrated.
Keywords: Canonical WNT signalling, frizzled receptors, novel signalling pathways, novel transmembrane proteins, Platelets, β-catenin, Thromboxane, Adenosine diphosphate, Ephrins, mass spectrometry, transmembrane receptor, CLEC-2
Current Proteomics
Title: Novel Platelet Signalling Pathways Identified via Proteomics
Volume: 8 Issue: 3
Author(s): Patricia B. Maguire, Brian M. Steele and Desmond J. Fitzgerald
Affiliation:
Keywords: Canonical WNT signalling, frizzled receptors, novel signalling pathways, novel transmembrane proteins, Platelets, β-catenin, Thromboxane, Adenosine diphosphate, Ephrins, mass spectrometry, transmembrane receptor, CLEC-2
Abstract: Unbiased proteomic analyses of cell fractions, interactomes and protein modifications coupled with more targeted approaches are adding to an impressive database of the signalling pathways in platelets. In addition to the well characterised receptors that are known to exist on the platelet surface, platelet proteomic studies continue to expose novel transmembrane proteins including CD148, CLEC-2, Eph kinases and Ephrins, Frizzled-4 and -6, G6b, HIP-55, HSP47, LRP5/6 and PEAR-1. In turn identification of novel platelet receptors has led to the discovery of new platelet signalling pathways such as the collagen/CLEC-2 receptor pathway, as well as the canonical WNT pathway. This review focuses on the canonical WNT pathway, providing background information to WNT ligands, receptors and signalling pathways and then focusing on canonical WNT signalling in anucleate platelets, where the suppression of platelet activity and adhesion by its ligand, Wnt-3a has recently been demonstrated.
Export Options
About this article
Cite this article as:
B. Maguire Patricia, M. Steele Brian and J. Fitzgerald Desmond, Novel Platelet Signalling Pathways Identified via Proteomics, Current Proteomics 2011; 8 (3) . https://dx.doi.org/10.2174/157016411797247503
DOI https://dx.doi.org/10.2174/157016411797247503 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Development of Small Molecule Glutaminase Inhibitors
Current Topics in Medicinal Chemistry Roles of miRNA in the Initiation and Development of Colorectal Carcinoma
Current Pharmaceutical Design Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models
Clinical Cancer Drugs Effect of PUFAs Oral Administration on the Amount of Apoptotic Caspases Enzymes in Gastric Cancer Patients Undergoing Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Role of Copper in Angiogenesis and Its Medicinal Implications
Current Medicinal Chemistry ABCB1, SLCO1B1 and UGT1A1 Gene Polymorphisms Are Associated with Toxicity Line Irinotecan
Drug Metabolism Letters Novel Nanotechnology Approaches for Targeted Cancer Therapy
Recent Patents on Nanomedicine Preparation and Primary Bioevaluation of 99mTc-labeled-1-thio-β-D-Glucose as Melanoma Targeting Agent
Current Radiopharmaceuticals Significance of Prion and Prion-Like Proteins in Cancer Development, Progression and Multi-Drug Resistance
Current Cancer Drug Targets Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Crosstalk between IGF-1R and other Tumor Promoting Pathways
Current Pharmaceutical Design Long Non-Coding RNA: An Emerging Paradigm of Pancreatic Cancer
Current Molecular Medicine Combinations of Plant Polyphenols & Anti-Cancer Molecules: A Novel Treatment Strategy for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry L-Arginine Modulates Glucose and Lipid Metabolism in Obesity and Diabetes
Current Protein & Peptide Science Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets A Partial Failure of Membrane Protein Turnover May Cause Alzheimers Disease: A New Hypothesis
Current Alzheimer Research Recent Patents on Live Bacteria and their Products as Potential Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Cyclopentenyl Cytosine (CPEC): An Overview of its in vitro and in vivo Activity
Current Cancer Drug Targets Improved Immunogenicity Against a Her2/neu-Derived Peptide by Employment of a Pan HLA DR-Binding Epitope and CpG in a BALB/c Mice Model
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetics of 3’-O-Retinoyl-5-fluoro-2’-deoxyuridine (RFUdR), a Dual Acting Mutually Masking Prodrug, and Its Metabolites in Tumor Bearing Mice
Current Drug Delivery